

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 18 August 2014 – On 7 August 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 7 August 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 7 August 2014 to 28 October 2014.

Since the announcement as of 7 August 2014, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	-		-
7 August 2014	230,000	248.99	57,267,102
8 August 2014	210,000	244.58	51,362,220
11 August 2014	250,000	248.38	62,095,375
12 August 2014	250,000	246.35	61,587,225
13 August 2014	210,000	245.75	51,607,500
14 August 2014	210,000	246.79	51,825,837
15 August 2014	260,000	249.11	64,768,054
Accumulated under the programme	1,620,000		400,513,313

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 93,975 B shares in the period from 7 August 2014 to 15 August

2014. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 36,267,039 B shares of DKK 0.20, corresponding to 1.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 15 August 2014, Novo Nordisk has repurchased a total of 33,357,995 B shares equal to a transaction value of DKK 8,105,031,812.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Katrine Sperling	+45 4442 6718	krsp@novonordisk.com
------------------	---------------	--

Investors:

Kasper Roseeuw Poulsen	+45 3079 4303	krop@novonordisk.com
Jannick Lindegaard Denholt	+45 3079 8519	jlis@novonordisk.com
Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com